Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study.
Otol Neurotol
; 26(5): 1022-6, 2005 Sep.
Article
em En
| MEDLINE
| ID: mdl-16151353
OBJECTIVE: To establish whether the oral administration of moderate doses of prednisone reduces refractory vertigo in Ménière's disease. STUDY DESIGN: Blinded, randomized, controlled trial. SETTING: Tertiary referral center. PATIENTS: Patients with Ménière's disease with limited vertigo control (Class C) and severe disability (Scale 3). INTERVENTIONS: Two groups (n = 8 per group) were treated orally with either diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h) (control group), or the same treatment plus prednisone (0.35 mg/kg) daily for 18 weeks (prednisone group). MAIN OUTCOME MEASURES: The variables evaluated were the frequency and duration of vertigo, tinnitus, aural fullness, and audiographic parameters. The clinical surveillance was performed for 12 months after prednisone withdrawal. RESULTS: The frequency and duration of vertigo episodes were reduced by 50% and 30%, respectively, by prednisone treatment. Prednisone-treated patients manifested a significant reduction in tinnitus. No changes were observed in aural fullness or hearing. No metabolic or infectious disorders were observed. CONCLUSION: Oral prednisone helps to control refractory vertigo in Ménière's disease. These preliminary data suggest that prednisone can be a good noninvasive antivertigo management regimen for these patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Prednisona
/
Vertigem
/
Glucocorticoides
/
Doença de Meniere
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Otol Neurotol
Assunto da revista:
NEUROLOGIA
/
OTORRINOLARINGOLOGIA
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
México
País de publicação:
Estados Unidos